PharmiWeb.com - Global Pharma News & Resources

Biotech - Press Releases

Date Title Company
09-Jul-2024 Professor Edith Heard appointed new Director and Chief Executive of the Francis Crick Institute The Francis Crick Institute
09-Jul-2024 Microbiotica to Present Positive Update on Manufacturing Progress of its Live Biotherapeutic Products for Forthcoming Melanoma and Ulcerative Colitis Clinical Studies Microbiotica
09-Jul-2024 Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution offering critical predictions to people living with diabetes Roche
09-Jul-2024 iOnctura announces expansion of roginolisib clinical trial program to NSCLC iOnctura
09-Jul-2024 MIG Capital co-leads €63 million Series A round for autoimmune biotech SciRhom MIG Capital
09-Jul-2024 ABPI responds to Wes Streeting’s commitment to boosting the economy through the life sciences sector Association of the British Pharmaceutical Industry (ABPI)
09-Jul-2024 IMFINZI▼(DURVALUMAB) in combination with chemotherapy APPROVED IN GREAT BRITAIN for the treatment of resectable non-small cell lung cancer AstraZeneca
09-Jul-2024 Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development Myricx Bio
09-Jul-2024 Pascal Piedbois, MD, PhD joins One2Treat as Chief Medical Officer to advance patient-centric innovation in clinical trial design and market access One2Treat
09-Jul-2024 Axoltis Pharma welcomes Jean-Guillaume Lafay as member of Supervisory Board  Andrew Lloyd Associates
08-Jul-2024 Spur provides update on FLT201 and planned Phase III clinical trial Syncona Limited
05-Jul-2024 CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe CSL
05-Jul-2024 CNX Therapeutics Announces CFO Transition: Olga Lund to depart, Claire Masterson Joins as new CFO CNX Therapeutics
05-Jul-2024 HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status HUTCHMED
05-Jul-2024 Launch of Phase 3 clinical trial with Nefecon in Japan Calliditas Therapeutics
05-Jul-2024 HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status HUTCHMED
05-Jul-2024 Anacura acquires OHMX.bio, adding multi-omics for drug discovery and diagnostics to its services. Anacura
04-Jul-2024 CPHI South East Asia opens as growth prospects outlined for pharmaceutical development in Vietnam, Thailand and Cambodia CPHI South East Asia
03-Jul-2024 LEO Pharma, Allergy UK and Expert Taskforce Uncover the Real Burden of Living with Chronic Hand Eczema (CHE) in New Report LEO Pharma
03-Jul-2024 Medigene AG Expands Patent Portfolio with the Patent Grant for its NY-ESO-1/LAGE 1a Targeted T Cell Receptor in China Medigene AG